About: Zileuton

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Zileuton Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B55CD-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B55CE-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Berger W, De Chandt MT, Cairns CB: Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007 Apr;61(4):663-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17394438 # Wenzel SE, Kamada AK: Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother. 1996 Jul-Aug;30(7-8):858-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8826571 # Malo PE, Bell RL, Shaughnessy TK, Summers JB, Brooks DW, Carter GW: The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm Pharmacol. 1994 Apr;7(2):73-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8081074 (en)
http://linked.open...gy/drugbank/group	approved (en) withdrawn (en) investigational (en)
http://linked.open...drugbank/halfLife	2.5 hours (en)
http://linked.open...ugbank/indication	For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. (en)
http://linked.open...bank/manufacturer	Blenheim Pharmacal
sameAs	Zileuton Zileuton
Title	Zileuton (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/chebi/10112 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/chemspider/54531 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/drugbank/DB00744 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/kegg-drug/D00414 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/national-drug-code-directory/68734-700-10 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/pharmgkb/PA451955 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/pubchem-compound/60490 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/pubchem-substance/46506394 http://linked.opendata.cz/resource/drugbank/drug/DB00744/identifier/wikipedia/Zileuton
http://linked.open...mechanismOfAction	Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in <i>in vitro</i> systems. Due to the role of leukotrienes in the pathogenesis of asthma, modulation of leukotriene formation by interruption of 5-lipoxygenase activity may reduce airway symptoms, decrease bronchial smooth muscle tone, and improve asthma control. (en)
http://linked.open...drugbank/packager	Cornerstone Pharmacy Altura Pharmaceuticals Inc. Abraxis pharmaceutical products Apotheca Inc. A-S Medication Solutions LLC
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/4873259 http://linked.opendata.cz/resource/drugbank/patent/5422123
http://linked.open...outeOfElimination	Elimination of zileuton is predominantly via metabolism with a mean terminal half-life of 2.5 hours. The urinary excretion of the inactive N-dehydroxylated metabolite and unchanged zileuton each accounted for less than 0.5% of the dose. (en)
http://linked.open.../drugbank/synonym	Zileuton (en) Leutrol (en) Zyflo (en) (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea (en) N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea (en) N-[1-(Benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea (en) Zileutonum (en)
http://linked.open...drugbank/toxicity	The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively). (en)
http://linked.open...umeOfDistribution	* 1.2 L/kg (en)
http://linked.open...nk/proteinBinding	93% bound to plasma proteins, primarily to albumin. (en)
http://linked.open...ynthesisReference	Emanuele ATTOLINA, Gianmaria Dell'Anna, Roberto Rossi, Pietro Allegrini, Gabriele Razzetti, "PROCESS FOR THE PREPARATION OF ZILEUTON." U.S. Patent US20090286996, issued November 19, 2009. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0175142
foaf:page	http://www.drugs.com/cdi/zileuton.html http://www.rxlist.com/cgi/generic/zileuton.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B55D3-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B55D9-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B55D8-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B55D5-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B55D6-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B55D7-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B55D1-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B55E9-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B55CF-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B55D2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B55EB-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B55D0-363D-11E5-9242-09173F13E4C5
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B55DF-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B55E0-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B55DA-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B55DB-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B55DD-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B55DC-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B55DE-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapidly and almost completely absorbed. The absolute bioavailability is unknown. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	111406-87-2 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* Apparent oral cl=7 mL/min/kg (en)
http://linked.open...gbank/containedIn	Zyflo 600 mg filmtab Zyflo cr 600 mg tablet Zyflo CR 600 mg 12 Hour tablet Zyflo 600 mg tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B55E5-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B55E7-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B55E8-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B55EA-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B55E4-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B55E3-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B55E6-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B55D4-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B55E1-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B55E2-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software